What: Shares of Array BioPharma, a biopharmaceutical company focused on developing novel small molecule cancer drugs, surged just shy of 10% on Monday following a hefty price target hike from ...

NEW YORK (AP) — Pfizer is buying the cancer treatment company Array BioPharma in a deal worth $11.4 billion. Array has a combination therapy for BRAF-mutant metastatic melanoma, along with a pipeline ...

Array BioPharma Inc. of Boulder, Colo., and Celgene Corporation, a Summit-based biopharmaceutical company, have announced a research and development collaboration on the discovery, development and ...

What: Shares of Array BioPharma, a biopharmaceutical company that's focused on developing novel drugs to fight cancer, skyrocketed by 51% in January, based on data from S&P Capital IQ, after ...

Following Array Biopharma Inc (NASDAQ:ARRY) reporting positive top line results from part 2 of a late-stage study of its combo treatment candidate for metastatic and BRAF-mutant melanoma, Leerink ...

Getting your Trinity Audio player ready... Boulder’s Array BioPharma Inc. is merging with Pfizer Inc. in an $11.4 billion deal. The merger agreement was announced Monday. Array BioPharma is a ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

After reporting fiscal second-quarter financials that were better than hoped, Array BioPharma (NASDAQ: ARRY) saw its shares surge 11.3% as of 3:40 p.m. EST on Tuesday. Array BioPharma has said in the ...

BOULDER, Colo.--(BUSINESS WIRE)-- Array BioPharma Inc. (NASDAQ: ARRY) today announced a restructuring to extend its financial resources and to focus on the development of its key clinical programs.

Pfizer, Inc. PFE announced a definitive agreement to buy small cancer drugmaker, Array BioPharma Inc. ARRY for $48 per share in cash for a total enterprise value of approximately $11.4 billion. Pfizer ...

Boulder’s Array BioPharma Inc. is merging with Pfizer Inc. in an $11.4 billion deal. The merger agreement was announced Monday. Array BioPharma is a commercial stage biopharmaceutical company focused ...

Array BioPharma has said in the past that it thinks its Mektovi and Braftovi cancer drugs target indications that could be worth $1 billion. And while sales remain a long way from the billion-dollar ...